The study of 94 familial breast cancers [32] demonstrated RAD21 overexpression in 43%, 44% and 33% of BRCA1, BRCA2 and BRCAX tumours, respectively, and expression was associated with shortened cancer-specific overall survival (Hazards Ratio 1.66, p = 0.003). This evidence concerns the gene RAD21 and cancer.